Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy

被引：1

作者：

Nakatsuru, Kousei ^{[1
,2
]}

Tsubouchi, Kazuya ^{[1
,2
]}

Hirahata, Minori ^{[3
]}

Nakashima, Tadayuki ^{[1
]}

Takahata, Yuriko ^{[1
]}

Okamatsu, Yuki ^{[1
]}

Shiraishi, Yoshimasa ^{[2
]}

Okamoto, Isamu ^{[2
]}

Harada, Taishi ^{[1
]}

机构：

[1] Japan Community Hlth Care Org Kyushu Hosp, Dept Resp Med, Fukuoka, Japan

[2] Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, Fukuoka, Japan

[3] Japan Community Hlth Care Org Kyushu Hosp, Dept Hematol, Fukuoka, Japan

来源：

THORACIC CANCER | 2023年 / 14卷 / 22期

关键词：

acute myeloid leukemia; autoimmune hemolytic anemia; immune checkpoint inhibitors; lung cancer; myelodysplastic syndrome; NEOPLASMS;

D O I：

10.1111/1759-7714.15005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Therapy related-acute myeloid leukemia (t-AML) and myelodysplastic syndrome (t-MDS) are complications of chemotherapy and/or radiation therapy for malignant diseases. In this report, we describe a patient with advanced lung adenocarcinoma who developed autoimmune hemolytic anemia and MDS associated with a combination of atezolizumab and platinum-based chemotherapy. The patient showed progression from t-MDS to t-AML 20 months after the treatment was initiated. A combination of immune checkpoint inhibitor (ICI) and chemotherapy may increase the risk of developing therapy-related myeloid neoplasms. As the prognosis of t-AML and t-MDS is poorer than that of de novo AML and MDS, proper surveillance, follow-up, and treatment are needed throughout the course of immunotherapy.

引用

页码：2225 / 2228

页数：4

共 50 条

[31] THE TREATMENT OF ACUTE MYELOID-LEUKEMIA PRECEDED BY THE MYELODYSPLASTIC SYNDROME [J].

HAMBLIN, T .

LEUKEMIA RESEARCH, 1992, 16 (01) :101-108

[32] Editorial: Immunobiology and immunotherapeutics in myelodysplastic syndrome and acute myeloid leukemia [J].

Patel, Shyam A. ;

Isidori, Alessandro ;

Cerchione, Claudio ;

Aureli, Anna .

FRONTIERS IN IMMUNOLOGY, 2024, 15

[33] Association of loss of heterozygosity with cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome [J].

Pinheiro, R. F. ;

Serio, F. M. ;

Silva, M. R. R. ;

Briones, M. R. S. ;

Chauffaille, M. L. L. F. .

BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2008, 41 (07) :610-614

[34] Frequency of inherited variants in the MEFV gene in myelodysplastic syndrome and acute myeloid leukemia [J].

Serkan Celik ;

Cagatay Oktenli ;

Emrah Kilicaslan ;

Fatih Tangi ;

Ozkan Sayan ;

H. Onur Ozari ;

Osman Ipcioglu ;

Yavuz S. Sanisoglu ;

M. Hakan Terekeci ;

Alev A. Erikci .

International Journal of Hematology, 2012, 95 :285-290

[35] Optimal combination of immune checkpoint and senescence molecule predicts adverse outcomes in patients with acute myeloid leukemia [J].

Wang, Peipei ;

Zhang, Yuling ;

Cai, Qinghua ;

Long, Qingqin ;

Pan, Shiyi ;

Zhou, Wei ;

Deng, Tingfen ;

Mo, Wenjian ;

Wang, Shunqing ;

Zhang, Yuping ;

Wang, Caixia ;

Chen, Cunte .

ANNALS OF MEDICINE, 2023, 55 (01)

[36] Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study [J].

Sheshadri, Ajay ;

Goizueta, Alberto A. ;

Shannon, Vickie R. ;

London, David ;

Garcia-Manero, Guillermo ;

Kantarjian, Hagop M. ;

Ravandi-Kashani, Farhad ;

Kadia, Tapan M. ;

Konopleva, Marina Y. ;

DiNardo, Courtney D. ;

Pierce, Sherry ;

Zarifa, Abdulrazzak ;

Albittar, Aya A. ;

Zhong, Linda L. ;

Akhmedzhanov, Fechukwu O. ;

Arain, Muhammad H. ;

Alfayez, Mansour ;

Alotaibi, Ahmad ;

Altan, Mehmet ;

Naing, Aung ;

Mendoza, Tito R. ;

Godoy, Myrna C. B. ;

Shroff, Girish ;

Kim, Sang T. ;

Faiz, Saadia A. ;

Kontoyiannis, Dimitrios P. ;

Khawaja, Fareed ;

Jennings, Kristofer ;

Daver, Naval G. .

CANCER, 2022, 128 (14) :2736-2745

[37] Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways [J].

Taghiloo, Saeid ;

Asgarian-Omran, Hossein .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157

[38] An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome [J].

S Kojima ;

M Sako ;

K Kato ;

G Hosoi ;

T Sato ;

A Ohara ;

K Koike ;

Y Okimoto ;

S Nishimura ;

Y Akiyama ;

T Yoshikawa ;

E Ishii ;

J Okamura ;

M Yazaki ;

Y Hayashi ;

M Eguchi ;

I Tsukimoto ;

K Ueda .

Leukemia, 2000, 14 :786-791

[39] An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome [J].

Kojima, S ;

Sako, M ;

Kato, K ;

Hosoi, G ;

Sato, T ;

Ohara, A ;

Koike, K ;

Okimoto, Y ;

Nishimura, S ;

Akiyama, Y ;

Yoshikawa, T ;

Ishii, E ;

Okamura, J ;

Yazaki, M ;

Hayashi, Y ;

Eguchi, M ;

Tsukimoto, I ;

Ueda, K .

LEUKEMIA, 2000, 14 (05) :786-791

[40] Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies [J].

Platzbecker, Uwe ;

Chromik, Joerg ;

Kroenke, Jan ;

Handa, Hiroshi ;

Strickland, Stephen ;

Miyazaki, Yasushi ;

Wermke, Martin ;

Sakamoto, Wataru ;

Tachibana, Yoshifumi ;

Taube, Tillmann ;

Germing, Ulrich .

BMC CANCER, 2022, 22 (01)

← 1 2 3 4 5 →